Pharmaceutical

BridgeBio gears up for FDA review of acoramidis followi...

BridgeBio submitted the NDA with US FDA for the TTR stabiliser in December 2023 ...

Evotec partners with Crohn’s & Colitis Foundation for I...

Evotec has announced a collaboration with the Crohn's & Colitis Foundation to ad...

STAT+: U.K. sequencing study surfaces new findings abou...

The 100,000 Genomes Project is a major research endeavor to discover how our gen...

STAT+: Contributors to psychiatry’s bible, the DSM-5, g...

A new study found that 60% of the physicians who helped compile the APA’s offici...

JPM Day 3 had a cautiously optimistic outlook

In honor of JPM Week, you’re reading a special edition of our biotech newsletter...

STAT+: At JPM, Verve details plot to take genome editin...

STAT sat down with Verve Therapeutics CEO Sekar Kathiresan at #JPM24 to dig deep...

After grilling Fauci on Covid origins, House Republican...

Republicans want to explore tighter inspection and safety requirements for infec...

STAT+: Heated lawsuit between AdventHealth, MultiPlan a...

A lawsuit between a large hospital system and a dominant vendor that works for h...

Nearly 1 in 10 teens globally have used ‘budget Ozempic...

Nearly 1 in 10 adolescents have used non-prescription weight loss products, acco...

STAT+: Pharmalittle: We’re reading about Sanofi’s Olymp...

A 2020 FDA warning on the labeling that Singulair could cause aggression, agitat...

Advocates expect Supreme Court Idaho abortion decision ...

Activists on both sides of the abortion debate said they anticipate ongoing effo...

STAT+: Bayer’s promising menopause drug trial results h...

Bayer may soon join Astellas in offering an effective non-hormonal treatment for...

Opinion: Preventing health care violence in the ER requ...

Health care workers facing violence in the ER need more than just safety — they ...

STAT+: Morgan Health wants you to know it’s still here

JPMorgan's business unit Morgan Health, started to control its health care costs...

JPM Day 2 has arrived. Here are the can’t-miss moments ...

In honor of JPM Week, you’re reading a special edition of our biotech newsletter...

STAT+: FDA’s Peter Marks seems inclined to grant full a...

The FDA's Peter Marks joined STAT for an interview about accelerated approval an...